Lipikar AP+MAX
Itch control | Instant dry skin relief | Anti-relapse
Triple-action emollient-plus balm for ultra-dry to atopic-prone skin.
Proprietary Neurobioma technology to tackle itch, restore the skin barrier, and rebalance the skin microbiome.
Proprietary Neurobioma technology to tackle itch, restore the skin barrier, and rebalance the skin microbiome.
PROVEN RESULTS
Tested on atopic skin and in oncology patients under dermatological, ophthalmological and pediatric control
ELIGIBLE PATIENTS
Suitable from 0 to 100 years old, even for newborns – all skin tones (Fitzpatrick I-VI)
FAQ
How does it compare to 10% urea? ▼
Superior on all measures at Week 12 in a double-blind RCT (N=60): better SCORAD, TEWL, DLQI, hydration, and skin pH (Prakoeswa, 2025). Confirmed in a second independent RCT (Canchy et al., ISAD, 2024).
Is it safe for newborns? ▼
Yes. Tested under dermatological and paediatric control from the first days of life, with high response rates and good tolerance (Canchy et al., WCPD, 2025).
When do results appear? ▼
TEWL improvement vs urea is measurable from Week 4. Significant differences in SCORAD, DLQI, and hydration emerge between Week 8 and Week 12 (Prakoeswa, 2025).
Does it reduce steroid use? ▼
Yes — 31% less corticosteroid by weight vs standard emollient in a 28-day RCT (N=119; p=0.041) (Zelenkova, 2023).
What about patients with darker skin tones? ▼
Studies across Fitzpatrick I–VI confirm increased NMF levels and improved itch intensity across all skin tones (La Roche-Posay, AAD, 2025).
Clinical Evidence
Before (D0)
After (D28)
Proven results
Tested on skins with atopic background
6H
Visible efficacy
Effect after 6h, dry skin relief for long-lasting hydration
24H
Itch control
For a better quality of life day & night
72H
Moisturizing effect on all skin tones
Long lasting relief for ultra dry to atopic prone skin
*Clinical study, 75 subjects, 72h after stopping the product use once daily for 28 days.
**Consumer study on 139 subjects presenting itch sensations due to dryness. Result 24h after stopping product use following 15 days of product application once a day.
Proven results
Significant anti-inflammatory effects observed
*Studies conducted on a reconstructed human epidermis model mimicking atopic dermatitis
* TSLP (thymic stromal lymphopoietin), RANTES (regulated on activation,
normal T-cell expressed and secreted), and CCL2 (C-C Motif Chemokine
Ligand 2)
Safety
Tested under dermatological and ophthalmological control on adults
Tested under dermatological and pediatrics control on children and babies
Tested on skins with atopic background
Suitable for patients undergoing cancer treatments
Suitable from 1st days of life
Tested under dermatological and pediatrics control on children and babies
Tested on skins with atopic background
Suitable for patients undergoing cancer treatments
Suitable from 1st days of life
Ingredient Science
Explore the science behind the formula and how key ingredients work together to target the biological mechanisms underlying the skin concern
KEY ACTIVE COMPLEX
Neurobioma: Proteasyl + Aqua Posae Filiformis + Microresyl
Neurobioma Mode of Action
Routine
Application: Entire body and face, once a day
Patient Services